Veytics Intelligence
2026-10-12 · NASDAQ

Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsJohnson & Johnson's fiscal 2025 sales rose about 6% to $94.2 billion, and its net income includes a roughly $7 billion reversal of its talc reserve.

Ler o briefing completo da Veytics

Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.